Back

Citigroup keeps Regeneron at Neutral as eye-drug competition grows

Verifying
  • Citigroup maintained a Neutral rating on Regeneron Pharmaceuticals.
  • Kodiak Sciences reported positive Phase 3 results for its eye drugs.
  • Growing ophthalmology competition is challenging Regeneron’s key product, Eylea.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.